{'fraction_non_alphanumeric': 0.022556390977443608, 'fraction_numerical': 0.0037593984962406013, 'mean_word_length': 5.549180327868853, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Off-label drug information: regulation, distribution, evaluation, and related controversies.

Americans have historically had perhaps the world’s most rigorous regulatory system for the protection of medical product consumers.1 FDA regulations have, however, become less restrictive in recent years.2 In particular, Congress and the FDA have become more permissive with respect to the distribution of journal articles about off-label uses by manufacturers.1 The change in regulations has been highly controversial and has led to intense debate regarding the benefits and risks of this practice. Because the FDA does not have the manpower to monitor this activity and other potential channels for possible inappropriate off-label promotion by industry, alternative means of regulation may be needed.